NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study

PLoS One. 2021 Sep 7;16(9):e0256602. doi: 10.1371/journal.pone.0256602. eCollection 2021.

Abstract

Objective: Whether use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of incident Parkinson's disease (PD) remains unresolved. Here, we employed the Norwegian Prescription Database to examine whether NSAID use is associated with a lower incidence of PD.

Methods: We compared the incidence of PD among users of NSAIDs in a population-based retrospective study using the Norwegian Prescription Database from 2004 to 2017. In total 7580 PD patients were identified using dopaminergic therapy over time as proxy for PD diagnosis. Analyses were performed with minimum 90 and 365 defined daily dose (DDD) NSAID exposure, respectively. Time-dependent Cox regression model and a binary logistic regression analysis with a 5-year lag until PD diagnosis were performed for all NSAIDs.

Results: There was overall no decrease in incidence of PD among NSAID users compared to controls. Using a minimum of 90 or 365 DDD threshold of exposure produced similar results. Analysis of individual NSAIDs did not show difference in PD incidence compared to controls Age-specific incidence rates of PD were comparable to reported age-specific incidence rates in previous studies.

Interpretation: Our findings provide no evidence that cumulative high exposure to NSAIDs affects the risk of developing PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Databases, Factual
  • Female
  • Humans
  • Inflammation / complications
  • Inflammation / drug therapy*
  • Inflammation / epidemiology
  • Inflammation / pathology
  • Male
  • Middle Aged
  • Norway / epidemiology
  • Parkinson Disease / epidemiology*
  • Parkinson Disease / etiology
  • Parkinson Disease / pathology
  • Prescriptions
  • Proportional Hazards Models
  • Risk Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal

Grants and funding

B.B: This work was supported by grants from the Western Norway Regional Health Authority (F11470). https://helse-vest.no/en The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.